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ABSTRACT 
 
Smokeless tobacco products have existed for centuries and vary 
significantly across geographical regions.  The constituents found in each 
smokeless tobacco product depends on many factors, including social customs, 
manufacturing regulations, and the availability of local raw ingredients.  
Unfortunately, tobacco products have been linked to cancer over the past several 
decades, particularly of the oral cavity.  In this study, the carcinogenic profiles, 
relative risks of oral cancer, and usage trends for three unique smokeless 
tobacco regions (United States, Sweden, and India) will be evaluated in order to 
determine the relative safety for each product. 
In this paper, the chemical analysis of various products from United 
States, as well as Swedish snus and Indian gutkha were reviewed, to establish 
constituent profiles.  The main carcinogens evaluated were the tobacco-specific 
n-nitrosamines; gutkha displayed the highest values of these ingredients, with 
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snus displaying the lowest.  Studies examining the relative risks for oral cancers 
associated with each of the three region’s smokeless tobacco products were 
assessed.  Indian gutkha expressed the highest relative risk for developing oral 
cancers, and Swedish snus expressed the lowest (a very slight increased risk at 
that).  To establish usage habits for each region-specific smokeless tobacco 
product, various epidemiological studies were analyzed and showed that gutkha 
was the most prevalently used product in its respective region, with Swedish 
snus only slightly trailing in use.  Smokeless tobacco products were used the 
least in the United States. 
These studies concluded that the gutkha habits in India were the most 
damaging to the public health of the nation with regards to smokeless tobacco 
use, particularly due to the high prevalence of use and high relative risk of oral 
cancers.  In a purely chemical sense, Swedish snus was less harmful than the 
counterparts often sold in the United States.  Yet, with snus use significantly 
higher than smokeless tobacco use in the United States, it is thought that 
Sweden snus habits are more detrimental than those seen in the United States.  
However, smokeless tobacco is ultimately an unsafe practice in all three regions 
evaluated, and more should be done to remove carcinogens from the products 
and promote self-restraint for current users. 
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Introduction 
 
 Historical evidence shows that smokeless tobacco of some form have 
been used for thousands of years, most likely originating in South American and 
Southeast Asia (National Cancer Institute, Centers for Disease Control and 
Prevention, & Stockholm Centre of Public Health, 2002).  Through either chewing 
or sucking, an individual would release and absorb the nicotine found naturally 
within the tobacco, and desire for the associated psychotropic effect of nicotine 
has kept the habit alive for centuries. 
 It has only been within the last century or so that the detrimental effects of 
smokeless tobacco use have garnered attention, particularly with regards to 
cancers of the oral cavity and oropharynx.  However, with the significant 
differences in tobacco products and habits seen around the world, each 
individual product deserves individual attention with respect to cancer association 
and risk.   In this paper, smokeless tobacco products from three different regions 
(the United States, Sweden, and India) will be compared based on carcinogenic 
profile, trends of use, and associated cancer risk.  By the end of the literature 
review, the general safety of each regions smokeless tobacco culture will be 
discussed. 
 Before looking over the literature, the characteristics of the different 
smokeless tobacco products and proposed carcinogenic mechanisms will be 
briefly covered. 
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Loose Leaf Tobacco 
 Until the early 20th century, particularly in the Americas, loose leaf tobacco 
(often referred to as chewing tobacco) was the prominent form of tobacco 
consumed.  While manufacturing processes have certainly become more efficient 
and consistent with modern technology, loose leaf tobacco production varies little 
than historic production.  Loose leaf tobacco is manufactured using an air-curing 
process on cigar leaf tobacco (Stanfill et al., 2011).  The final product is then 
packaged in small, shredded strips into a bag.  Brands of loose leaf tobacco vary 
based on the size of the shredded strips and are often flavored and sweetened 
with molasses or simple syrup, a mixture of processed sugar and water; the 
sugar content tends to be near 35%.  Manufacturers often use licorice as one of 
these flavoring agents.  To use the product, the consumer will pinch the desired 
amount of chewing tobacco (doses are around 0.75 to 1 inch diameter) out of the 
bag and place in their mouth (National Cancer Institute (NCI) et al., 2002).  They 
will then either chew the tobacco or practice “dipping”.  Dipping refers to when 
the consumer places the smokeless tobacco product between the gums and jaw, 
particularly in front of the lower incisors/canine teeth or in the rear of the mouth 
(Borgerding et al., 2012). 
Loose leaf tobacco can also be manufactured in a “plug” form, 
characterized by the tobacco being pressed into bricks.  Plug tobacco also tends 
to use heavier grades of the tobacco leaf for structure (Stanfill et al., 2011).  
Moisture levels of the plug brick will determine whether the product is marketed 
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as “firm” or “moist” plug tobacco (Borgerding et al., 2012).  Additionally, “twist” 
tobacco is even another packaging option for chewing tobacco consumers.  Twist 
tobacco is recognized as a twisted rope of between one and three high grade 
tobacco leaves (Stanfill et al., 2011).  Twist tobacco products tend to have 
significantly less sweeteners added than traditional chewing tobacco (NCI et al., 
2002). 
 The tobacco variety used in smokeless tobacco products found in the 
United States is Nicotiana tabacum L.  This type of tobacco varies from the 
common Asian alternative Nicotiana rustica which expresses both a higher 
nicotine and tobacco-specific N-nitrosamines (TSNA) concentration than the 
alternative found in the United States market (Stanfill et al., 2011). 
 
Moist/Dry Snuff 
 While chewing tobacco remained the most popular smokeless tobacco 
option after the boom of the cigarette industry, the introduction of moist snuff in 
the early 1970s changed this trend.  In the United States population, moist snuff 
continues to be the most popular option among smokeless tobacco products.  
Dry snuff is a similar product with a few distinct differences (Stanfill et al., 2011). 
 Production of moist snuff starts with air or fire cured tobacco.  Following 
either process, the cured tobacco goes through the process of fermentation for a 
set time period determined by the manufacturer.  This fermentation process, 
involving the moistening and heating of the cured tobacco, leads to the high 
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levels of TSNAs and nitrite in the moist snuff.  These components are created by 
naturally found bacteria that are stimulated by the fermentation (Rodu & Jansson, 
2004).  Unlike loose leaf tobacco, neither the stems nor the seeds are removed 
from the tobacco leaves during manufacturing (NCI et al., 2002). 
 If this cured and fermented tobacco becomes moist snuff, the tobacco will 
then be ground into fine particles or cut into millimeter long strands.  Fine 
grinding or cutting snuff into these short strands increases the product’s surface 
area dramatically, which in turn increases nicotine absorption noticeably.  
Packing will either be loose tobacco in a tin or placed in small ready-to-use 
pouches, and either option is used in the same fashion as loose leaf tobacco.  
Moisture levels must maintain a minimal level of 25%, but a value closer to 50% 
is common practice (Borgerding et al., 2012).  If dry snuff is the final product 
desired, the cured and fermented tobacco will be finely ground into small 
particles and dried to a moisture level of less that 25%, but moisture usually 
hovers around 10%.  At this moisture and consistency, consumers may choose 
to inhale the dry snuff through the nasal passage in addition to using the product 
orally (NCI et al., 2002). 
 
Swedish Snus 
 Although technically considered to be of the moist snuff variety of 
smokeless tobacco, unique manufacturing procedures and production restrictions 
make Swedish snus a distinct product.  With daily snus use in Sweden hovering 
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around 20% with males and on the rise (yet still lower) with females, individual 
attention is importantly given to Swedish snus (Luo et al., 2007). 
 The major manufacturing difference between Swedish snus and traditional 
moist snuff, and the process which is responsible for the unique carcinogenic 
profile found in snus, is the replacement of fermentation with steam 
pasteurization (Coggins et al., 2012).  By pasteurizing the air-cured tobacco 
instead of applying fermentation, the resulting sterilization destroys the bacteria 
responsible for much of the TSNA and nitrite production (Rodu & Jansson, 2004).  
As expected, the values of these constituents found in Swedish snus are 
significantly lower than other moist snuff options and will be discussed in further 
detail.  In addition to the incorporation of steam pasteurization, Swedish snus 
manufacturers add sodium carbonate, sodium chloride, and humidifying agents 
to the list of ingredients.  The final, packaged product is kept refrigerated while 
being stored, another attempt to avoid the fermentation process in the tobacco 
and further reducing TSNA and nitrite amounts (NCI et al., 2002). 
 As with traditional moist snuff, users place either a pinch or pouch of snus 
between their gum and cheek/lip; placing snus behind the upper lip is common 
among snus users.  However, snus users will continue to leave the dose in their 
mouths for extended periods of time, often averaging around 11 to 14 hours a 
day.  Varying doses of pouched snus are also available for a snus user to choose 
from; either regular or “mini-portions”, at 1.0 g or 0.5 g of tobacco per dose, 
respectively (NCI et al., 2002). 
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Gutkha 
 Unlike the previous types of smokeless tobacco listed, Gutkha (also gutka) 
is unique in the sense that tobacco is not necessarily always the most prominent 
ingredient in this Southeast Asian product.  Any gutkha sample will likely have 
much less tobacco present than a smokeless tobacco product from either the 
American or European market; the total percent tobacco is lowered due to the 
addition of key ingredients such as slaked lime and, more importantly, the areca 
nut (Stanfill et al., 2011).  Common flavoring additives in gutkha include saffron, 
catechu, mustard, turmeric, and cloves, but the regional variety in percent 
composition and added ingredients is extreme (Centers for Disease Control and 
Prevention (CDC), 2011). 
 As mentioned, besides tobacco, the areca nut and slaked lime are the 
staple constituents found in the typical gutkha products.  When a betel leaf is 
included with the areca nut and slaked lime, the subsequent combination is 
known as betel-quid (also, ‘paan’), a common tobacco free chewing product.  
The Asian people use the areca nut in betel-quid and gutkha often enough to 
have it declared the “fourth most common psychoactive substance in the world”, 
following only caffeine, alcohol, and nicotine (Gupta & Ray, 2004).  Betel-quid is 
formed when processed areca nut is wrapped in a betel leaf that has been 
spread with slaked lime, often with other varying additives present.  Paan users 
will then chew or suck on the leaf-wrapped mixture until attaining the desired 
effect, either spitting or swallowing the saliva.  Unlike betel-quid, gutkha is not 
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wrapped in the betel leaf; gutkha more resembles chewing tobacco and moist 
snuff in both appearance and method of consumption. 
The areca nut is an additive native to the Southeast Asian market and 
derived from the areca palm plant, Areca catechu.  Though this species of the 
areca palm is most common, different species exist throughout Asia.  No matter 
the species, as noted by Gupta and Warnakulasuriya, areca nut use in Asian 
regions is “strongly interwoven into local art and craft, folklore, social customs, 
religious practices and cultural rituals.”  In processing, the manufacturer or user 
(when homemade) has many options in which to treat the raw areca nut before 
use.  Popular options include sun-drying or boiling the nuts before de-shelling, 
sometimes even burying them in moist pits allowing for fermentation to occur 
(Sharan et al., 2012).  People and literature often refer to the areca nut as the 
betel nut, but this is a misnomer and a result of its popular use with the betel leaf 
of the Piper betle plant (Sharan et al., 2012). 
Slaked lime (calcium hydroxide) isn’t, in and of itself, a potent carcinogen.  
However, the role it and other inorganic salts fill in smokeless tobacco products 
and betel-quid indirectly leads to higher incidents of harmful health effects of 
users.  Slaked lime is obtained in two fashions and depends on the geographical 
location of production.  In coastal regions, a process involving the heating of 
seashells is used; more inland regions incorporate quarried limestone into 
manufacturing (World Health Organization (WHO), 2004).  As an alkaline 
modifier, slaked lime will raise the pH level of a substance it is added to.  When 
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that substance includes nicotine as a constituent, a higher percentage of the total 
nicotine will be converted in to unionized (“free”) nicotine.  In the unionized form, 
nicotine is absorbed by the oral mucosa at a significantly faster rate and this, in 
turn, quickly increases the total blood nicotine concentration (Richter et al., 
2008).  Nicotine uptake has been widely established as the cause of tobacco 
product addiction, and the faster the faster the uptake, the higher the addictive 
potential. 
  
Tobacco-Specific N-Nitrosamines 
 Although the blame for the addictive potential of tobacco falls on the 
naturally occurring alkaloid and drug nicotine, it is the TSNAs that are 
responsible for a majority of the detrimental health effects experienced by 
smokeless and smoking tobacco users alike.  While there are several TSNAs 
present in smokeless tobacco products, the most detrimental are N’-
nitrosonornicotine (NNN), N’- nitrosoanatabine (NAT), N’-nitrosoanabasin (NAB), 
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Figure 1).  Of these 
four, NNN and NNK are the main TSNAs believed to play a significant role in the 
development of oral cancer of tobacco users (Stepanov, Jensen, & Hecht, 2008). 
The listed N-nitrosamines are formed in tobacco products by the 
nitrosation and sometimes reduction of the nicotine found in tobacco, leading to 
the “tobacco-specific” title given to them (Hoffmann et al., 1995).  While TSNAs 
are found in all tobacco products, the concentration and specific TSNAs found 
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depend entirely on type of tobacco plant, process used (or not used) during 
manufacturing, and constituent interactions.  Curing the tobacco, and the optional 
step of fermenting the cured-tobacco, both significantly alter the TSNA 
concentration.  The moisture level of the product and storage methods can 
further elevate the level after curing and fermentation (Borgerding et al., 2012).  
The mechanism of formation and chemical structure of the major TSNAs can be 
seen in Figure 1.  The carcinogenicity and carcinogenic mechanisms of TSNA 
and other smokeless tobacco carcinogens are discussed in further detail. 
 
 
Figure 1: TSNA formation and chemical structures.  Relevant abbreviations: N’-
nitrosonornicotine (NNN), N’- nitrosoanatabine (NAT), N’-nitrosoanabasin (NAB), 
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Hoffmann et al., 
1995). 
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Carcinogenic Mechanisms and Toxicity 
Tobacco-Specific N-Nitrosamines 
 As the most critical carcinogenic constituents found in most smokeless 
tobacco products, understanding the metabolism and role that TSNAs play in 
carcinogenesis is vital.  As most of the other detected TSNAs in tobacco 
products contribute negligibly to cancer risk, research maintains focus on both 
NNN and NNK (Nilsson, 2011).  While research on potential pathways are 
continuously being conducted and improved upon, and numerous possible 
mechanisms have been proposed, only several will be discussed within the 
scope of this paper. 
 Initially, biomarkers were established to provide evidence of TSNA uptake 
and to prove that TSNAs were actually metabolized in the body.  The TSNA NNK 
is metabolized into the body into several different metabolites, specifically 4-
(methyl-nitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and the glucuronides of NNK 
(Hecht, 1998).  Interestingly, while merely a metabolite of NNK, the carcinogenic 
properties of NNAL vary little to NNK.  Conversely, the glucuronides of NNK 
retain none of the carcinogenic potential expressed by NNK.  Analysts consider 
NNAL an ideal biomarker for tobacco usage, mainly for its “high reliability and 
specificity to tobacco products” of both the smokeless and smoking variety 
(Boffetta et al., 2008).  In order to measure total absorption and uptake of NNK, 
the amount of both NNAL and NNK glucuronide concentration can be detected in 
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the urine and combined.  Similar metabolites and glucuronides have been 
discovered for NNN and the other TSNAs. 
Another byproduct of NNN and NNK’s metabolic pathways is available not 
only for detection, but also as evidence of carcinogenic trends.  The cytochrome 
P450 enzymes, a superfamily of enzymes that metabolize a majority of drugs 
among having other roles, are known to interact with absorbed NNN and NNK to 
form pyridyloxobutyl (POB) diazonium ions (Jalas, Hecht, & Murphy, 2005).  
Once formed, these POB diazonium ions may then react with hemoglobin and 
form DNA adducts ( a DNA molecule attached to a carcinogen) and subsequently 
release the compound 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) (Hecht, 1998).  
DNA adducts of all types are notorious for their tendency to cause DNA 
miscoding and mutation errors, key components of carcinogenesis (Nilsson, 
2011).  HPB, the final compound released from this pathway, is the biomarker 
often used to detect NNN and NNK. 
 These biomarkers are important when comparing TSNA absorption 
between tobacco products, either smoking or smokeless.  For example, one 
study compared smokeless tobacco users’ NNK absorption to that of smokers 
using total urinary NNAL as the metric; smokeless tobacco users showed 
significantly higher concentrations.  A similar study was performed with NNN 
absorption and the detectable urinary HPB, and smokeless tobacco users 
(particularly snuff) again expressed higher concentrations of total urinary HPB 
than smokers (Hecht et al., 2007). 
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 Highlighting on the danger of the DNA adducts formed by NNK and NNN 
helps to explain the damage potential of TSNAs found in tobacco.  These DNA 
adducts form in tissues that are directly exposed to the TSNAs such the oral 
cavity when smokeless tobacco products are used (Hecht, 1998).  DNA adducts 
are not immediately detrimental, however, as the natural DNA repair cycle has 
the opportunity to reverse the damage.  If not repaired, mutations and miscoding 
may then occur.  Vulnerable DNA regions for these errors include the RAS 
oncogene and the P53 tumor suppressor gene, responsible for promoting and 
suppressing carcinogenesis respectively (Warnakulasuriya & Ralhan, 2007).  
Severe enough DNA damage may arrest the cycle of affected cells and therefore 
induce neoplastic growth.  Figure 2 illustrates this process with a simple flow 
chart.  Furthermore, other carcinogenic promoting processes brought on by 
smokeless tobacco include oxidative stress, chronic local inflammation, and oral 
lesion formation.  No matter the underlying cause, only repetitive exposure to 
tobacco carcinogens will lead to carcinogenesis over an extended period of time 
(Boffetta et al., 2008). 
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 With a unique delivery of tobacco and accompanying toxins to the body, a 
study by Wang and colleagues focused on NNK’s role in laryngeal carcinoma, 
slightly associated with dry snuff use.  Only nasal inhalation of dry snuff exposes 
laryngeal cells to TSNAs when disregarding smoking tobacco.  In the laboratory, 
the TSNA NNK has shown to increase protein levels of the enzyme DNA 
methyltransferase 1 (DNMT 1).  The increased concentration levels of this 
enzyme then will hypermethylate tumor suppressor genes in laryngeal tissue 
cells, specifically laryngeal squamous cells.  The particular laryngeal squamous 
cell concentrated on this study was of the Hep-2 variety (Wang et al., 2012).  
Normal DNA methylation, which plays a key role in cell growth management, is 
then compromised and can lead to carcinogenesis.  Similar mechanisms of 
tumorgenesis by hypermethylation are seen in other cancers of the body that are 
not associated with tobacco use.  So while these results were only observed 
under laboratory conditions, further studies may show similar mechanisms 
caused by NNK in vivo (Wang et al., 2012). 
 
Areca Nut 
 An essential component of gutkha, the Areca nut and its impact on the 
carcinogenicity of products must be explored.  Chemically the most detrimental 
compounds observed in the Areca nut are the alkaloids and tannins, particularly 
the alkaloid arecoline, but Figure 3 shows other potential oncogenic 
mechanisms.  Arecoline, along with having the greatest carcinogenic 
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significance, is also the most abundant alkaloid in the Areca nut (Sharan et al., 
2012). 
 One experiment focused on the effects of Areca nut extract and the 
alkaloid arecoline on SAS oral epithelial cells as both are known for 
demonstrating genotoxicity (Ko et al., 1992).  These analytes were used in 
assays to test this claim.  The first assay checked for CHK1 and CHK2 activation 
by the extract or arecoline.  Both CHK1 and CHK2 are checkpoint kinases and 
are integral in DNA repair during the cell cycle; activation of these kinases 
indicate damage to the DNA.  Their activations can eventually lead to alteration 
of the cell cycle and apoptosis.  Twenty-four hour exposure to either analyte 
marked an increase of CHK1 and CHK2 phosphorylation in the SAS cells, a 
display of kinase activation (Chang et al., 2012). 
The MMP-9 assay of these analytes provided further genotoxicity 
evidence.  Metalloproteinase-9, an inflammatory mediator, plays a role in the 
inflammatory response and can lead to cellular proliferation, angiogenesis, and 
ultimately metastatic cancer (Chang et al., 2012).  High levels of this mediator 
are associated with oral squamous cell carcinoma.  Following treatment with the 
Areca nut extract, SAS cell MMP-9 levels increased by a factor of two or more, 
depending on concentration levels.  Oddly, arecoline exposure instead caused a 
decrease in MMP-9 levels, more so with higher arecoline concentration levels.  
The reduction may be attributed to the cytotoxicity of arecoline that has been 
determined in other earlier studies (Chang et al. 2012). 
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Arecoline is also linked to the inhibition of the tumor suppressor gene p53.  
One study involved an assay exposing KB and HEp-2 cells, both well-established 
cancer cell lines, to arecoline.  Results determined that arecoline repressed 
expression of the p53 gene; further testing exhibited p53 mRNA repression and 
inhibition of p53 target genes (Tsai et al., 2008).  The exact mechanism of this 
inhibition has yet to be determined but may involve inhibited promoter gene 
activity.  Even so, Tsai et al. believe this inhibitive property of arecoline “should 
play a critical role in the tumorigenesis” of Areca nut related cancers. 
 According to Wang and colleagues, 
“dysregulation of the caretaker genes lead to an increase 
in the overall rates of DNA damage, mutation, and 
chromosomal missegregation.” 
 
The spindle assembly checkpoint gene falls into this “caretaker” category.  
The checkpoint prevents mitotic progress into metaphase if the chromosomes 
are misaligned by the microtubules and will become inactive once the 
chromosomes align properly.  The effect of arecoline on the spindle assembly 
checkpoint was analyzed by treating KB and HEp-2 cells and microscopically 
determining if the cells get held in the prometaphase stage (Wang et al., 2010).  
Prometaphase is marked by the nuclear envelope dissolving and microtubules 
attaching to the kinetochores at the chromosome centers (Malmanche et al., 
2006).  The arecoline treatment matched the concentration found in the saliva of 
gutkha users to mimic those conditions.  Treatment caused over 50% of the KB 
and HEp-2 cells to remain in prometaphase compared to the 10% found in the 
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control.  Additionally, spindle assembly checkpoint genes appeared upregulated, 
possibly a result of the checkpoint trying to correct the cellular arrest (Wang et al. 
2010).  Malmache and colleagues tell how “a weakened [spindle assembly 
checkpoint] could facilitate tumour development in cells that are undergoing 
tumorigenesis.” 
 Similar to the TSNAs found in tobacco, areca nut-specific N-nitrosamines 
have been discovered and detected in users of areca nut products.  The notable 
N-nitrosamines are 3-methylnitrosamino-propionaldehyde (MNP), 3-
methylnitrosamino-propionitrile (MNPN), N-nitrosoguvacine (NGC), and N-
nitrosoguvacoline (NGL).  These compounds are all derived from the alkaloid 
arecoline and seem to be created during the chewing process and blending with 
saliva.  (WHO, 2004).  Although no studies have been completed to determine 
the carcinogenic potential of these areca nut nitrosamines in humans, this 
potential has been seen in rats. 
 
Combination of Areca Nut and Tobacco 
 In 2011, Joshi et al. explored the combined toxic effect of both areca nut 
and tobacco carcinogens in buccal mucosal (cheek) cells of gutkha chewers 
using a micronucleus assay, as micronuclei are the “biomarker of genetic 
damage in buccal mucosal cells” (Stich and Rosin, 1983).  Cells that were either 
micronucleated or showed evidence of other nuclear anomalies were noted.  The 
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study involved both chewers and non-chewers of gutkha with each participant 
having 1000 buccal cells assayed. 
Assay results showed an increase in frequency of micronuclei in the 
buccal mucosal cells of gutkha chewers (0.57 + 0.08) when compared to non-
chewers.  Similarly, with all other nuclear anomalies included, the total frequency 
of normal differentiated cells in chewers (85.81 + 0.98) was lower than non-
chewers (88.42 + 0.53) (Joshi et al., 2011).  These findings support the belief that 
the constituents in gutkha, as seen in other tobacco products, are genotoxic. 
 The assay results reinforce another claim, that frequency of use is directly 
related to cellular damage done.  A dose-dependent relation was exhibited in the 
micronuclei frequency among gutkha chewers.  For those that used gutkha five 
times or less throughout a single day, the frequency was determined at 0.70.  
When gutkha use reached or surpassed ten times a day, micronuclei frequency 
reached 0.90 (Joshi et al., 2011). 
 
Carcinogenic Profiles 
United States 
 While the carcinogenic mechanisms of most smokeless tobacco 
component are established, the abundance of a component in smokeless 
tobacco products is imperative to understanding its effect on cancer risk. 
 A recent large investigation evaluated the chemical composition of 43 
different US brands of various types of smokeless tobacco sold between 2006 
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and 2007.  Past chemical studies of smokeless tobacco tended to only review a 
few brands and types, so the significance of the review can be found in its 
inclusion of many brands for each major tobacco type across each price range.  
The major tobacco types included in this survey are moist and dry snuff, loose 
leaf, dissolvable, and plug.  The methods used for composition analysis follow 
protocol presented by Health Canada, AOAC INTERNATIONAL, and LabStat, 
and were repeated three times to establish accuracy (Borgerding et al., 2012).  
The ingredients analyzed were, NNN, NAT, NNK, NAB, nitrite, metals (cadmium, 
lead, arsenic, nickel, chromium, chloride), and nicotine. 
 The mean total TSNA (NNN, NAT, NAB, NNK) concentrations for each US 
tobacco type were determined and were ranked from least to highest: dissolvable 
(399 ng of total TSNA / g of product), loose leaf (3350 ng/g), plug (8388 ng/g), 
moist snuff (9786 ng/g), and dry snuff (14,768 ng/g).  Some individual brand’s 
total TSNA concentrations reached upwards of 40,000 ng/g.  Even though dry 
snuff in the tested brands had the highest mean concentration, the range was 
broad and some brands were significantly lower than others coming in as low as 
1750 ng/g.  In all of the US tobacco types, with the exception of dissolvable 
tobacco, NNN had the highest recorded mean concentration for individual 
TSNAs.  Conversely, NAB had the lowest mean concentration across all tobacco 
types (Borgerding et al., 2012). 
 Similar to the TSNA results, dry snuff and moist snuff had the highest and 
second highest mean concentration of toxic metals among US smokeless 
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tobacco products at 768 ng/g and 5239 ng/g, respectively.  Loose leaf tobacco 
had the lowest value in this category.  When breaking down the total toxic metal 
concentrations into individual metal concentration, mean concentrations did vary 
wildly among product types and brands.  For instance, while moist snuff had the 
highest mean concentration of arsenic (214 ng/g), chromium recorded higher in 
dry snuff (2838 ng/g).  The US snus brands had the lowest mean total metal 
concentrations in their respective dry and moist snuff varieties (Borgerding et al., 
2012). 
 Although not directly carcinogenic, nitrite and nicotine values are important 
statistics to consider.  The concentration pattern continues with nitrite, exhibiting 
overall higher concentrations in moist and dry snuff when compared to other 
varieties.  As mentioned earlier, nitrite acts as a nitrating agent and can form 
TSNAs during the processing and storage of tobacco, thereby increasing 
carcinogenicity.  The high nitrite concentrations observed in the snuff products 
indicate future rises in total TSNA concentrations throughout the product life.  
Mean nicotine concentrations, representing the element responsible for the 
addictive property of tobacco, ranged from 6.0 to 15.8 mg/g.  The more 
bioavailable “free nicotine” made up between 0.5% and 36.0% of the total 
nicotine concentration in smokeless tobacco products.  Moist snuff made up the 
largest portion of smokeless tobacco products at the top end of “free nicotine” 
concentrations, ranging all the way up to 68.0% (Borgerding et al., 2012).  Table 
1 summarizes the findings for several of the categories discussed. 
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Table 1: Smokeless tobacco component levels determined in US brands 
(Borgerding et al., 2012). 
 
Tobacco 
Type 
Products 
Tested 
Total 
TSNA 
 
(ng/g) 
NNN 
 
 
(ng/g) 
NNK 
 
 
(ng/g) 
Nitrite 
 
 
(µg/g) 
"Free 
Nicotine" 
(% of Total 
Nicotine) 
Dissolvable 2 399 107 <114 4.9 16.1 
Loose Leaf 7 3350 1798 523 5.3 0.5 
Plug 1 8388 5053 1230 6.1 0.9 
Moist Snuff 23 9786 4058 1394 113.5 36 
Dry Snuff 10 14,768 5535 2522 9.3 4.8 
 
 Unlike the previous study, the aim of the analysis on smokeless tobacco 
carcinogen levels by Stepanov and colleagues was to compare levels in newer 
products to traditional brands.  Two relatively new US snus brands (Camel Snus 
and Marlboro Snus), a dry snuff (Skoal Dry), and a snus-like product named 
Taboka.  All of these newer products are sold as pouches placed around gums, 
and do not require spitting, mirroring the delivery method of Swedish products.  
Different flavors of these brands were analyzed and compared against popular, 
traditional moist snuff as well as a Swedish snus product.  TSNA, nitrate/nitrite, 
and PAH concentrations were determined by gas (TSNA) and ion (nitrate/nitrite, 
PAH) chromatography (Stepanov et al., 2008).  Chemical extractions were 
performed before analysis and followed a protocol of tobacco homogenization, 
high speed centrifugation, and chemical washes (Stepanov et al., 2005). 
 Results show that all of the newer tobacco products analyzed had lower 
NNN values than traditional moist snuff products with exclusion of Marlboro Snus 
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Mint and Skoal Dry.  This particular mint snus had a NNN concentration similar to 
traditional moist snuff at 3.28 µg of NNN per gram of tobacco.  NNK 
concentrations were lower in all of the new tobacco products when compared to 
the traditional moist snuff products; Taboka exhibited the lowest level among all 
the new products.  Overall, the total TSNA concentration found in the new 
products was lower than the traditional counterparts in comparison with Skoal dry 
having the highest.  The nitrite levels in the newer products were ten times lower 
than traditional products, lowered from 0.030 mg of nitrite per gram of tobacco to 
0.0030 mg/g.  Similarly, nitrate was also determined to be lower but by only a 
factor of three.  Observed polycyclic aromatic hydrocarbon (PAH) concentration 
followed the trend and was significantly lower in all newer products (Stepanov et 
al., 2005). 
 
Sweden 
Unique in chemical and physical composition for a moist snuff, Swedish 
snus displays a significantly different carcinogenic profile than the traditional 
smokeless tobacco types found in the American market.  Manufacturing 
procedures and practices account for the distinct ingredient values and 
proportions.  Due in part because of strict production protocol found in the 
Swedish smokeless tobacco industry to be discussed later, data revealing snus’ 
profile is readily available. 
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A particular study reviewing the composition of smokeless tobacco 
products around the global market was performed at the Centers for Disease 
Control’s (CDC) Tobacco Analysis Laboratory in 2011.  While the laboratory 
reviewed a total of 53 smokeless tobacco products from several different World 
Health Organization (WHO) regions, five popular Swedish snus products were 
extensively evaluated.  Chemical profiles which included the composition, 
nicotine quantification, and TSNA level of each product were created through the 
use of spectroscopy, gas chromatography, and mass spectrometry (Stanfill et al., 
2011). 
Table 2: Swedish Snus component levels found in 5 popular brands (Stanfill et 
al., 2011). 
 
Brand Name Mean Total 
TSNA 
 
(ng/g) 
Mean NNK 
 
 
 (ng/g) 
Mean NNN 
 
 
(ng/g) 
Mean “Free” 
Nicotine 
(% of Total 
Nicotine) 
General 
Original Snus 
723 96.4 345 8.98 
General 
Loose Snus 
652 105 293 3.77 
General White 
Wintergreen 
Snus 
601 89.8 267 10.0 
General White 
Portion Snus 
648 96.8 296 6.48 
Catch 
Peppermint 
Snus 
630 84.5 295 13.3 
 
Study results display a pH of the Swedish snus products ranging from 
6.61 to 6.86.  Paired with nicotine levels between 7.76 and 15.2 mg/g, the 
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determined percent of bioavailable free nicotine in the Swedish snus products 
stretched from 3.77% up to 13.3%.  These percentages vary significantly from 
and are much lower than the 36% average found for the 23 American moist snuff 
products discussed previously.  Differences in this value could explain any 
possible differences in the addictive potential of Swedish snus when compared to 
their American counterparts (Stanfill et al., 2011). 
Stanfill’s study of Swedish snus TSNA values focused on the specific N-
nitrosamines NNK, NAT, NNN, and NNAL.  The ranges of each TSNA in the five 
tested snus products were quite small, as can be seen in Table 2.  The highest 
total TSNA value recorded was from the General Original Snus sample at 723 
ng/g of tobacco.  As was seen with the comparison between Swedish snus and 
American moist snuff free nicotine percentages, even the snus sample with the 
highest total TSNA was significantly lower than the American total TSNA average 
of 9786 ng/g.  The values for NNK and NNN found in Swedish snus follows this 
trend and also display significantly lower values.  Nitrite values were not studied 
in this experiment and thus not available for comparison (Stanfill et al., 2011).  It 
is important to note that this study only reviewed 5 snus products (numerous 
samples of each), 4 of which came from the same manufacturer, so a larger 
sample size could provide even stronger evidence. 
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India 
 The carcinogenic profile of gutkha is extremely difficult to assess due to 
the wide variety of types seen and lack of manufacturing regulation.  The Stanfill 
review provides a great example of how much carcinogen presence can vary in 
the gutkha market.  The total TSNA range (in ng TSNA per gram of product) 
stretched remarkably from 83.9 all the way up to an astounding 23,900 ng 
TSNA/g (Stanfill et al., 2011).  This incredibly high TSNA value was seen in one 
of the handmade varieties of gutkha; other handmade gutkha products had only 
slightly lower total TSNA values than this extreme value.  Disregarding high-
TSNA count handmade gutkha, most Indian gutkha TSNA levels closely 
resembled Swedish snus values.  This low TSNA value for the highly 
carcinogenic gutkha products can be attributed to the low percent of tobacco 
used in them.  Betel-quid presence decreases the “ng TSNA per g product” value 
via dilution. 
 An additional problem with establishing gutkha’s carcinogenic profile is 
quantifying levels of the betel-quid carcinogens.  When gutkha is analyzed with 
other smokeless tobacco products, only common compounds are included in the 
metrics (nicotine, TSNAs, etc.)  This leaves betel quid-specific carcinogens such 
as arecoline and areca nut-specific N-nitrosamines, which are not found in most 
other smokeless tobacco products, too often ignored.  Relative risk 
determinations for gutkha and related cancers may be the only effective current 
method to quantify gutkha’s carcinogenic potential. 
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Epidemiology of Smokeless Tobacco Use 
United States 
 As smokeless tobacco use was first recognized as a public health problem 
in the United States in the mid-1980’s, this epidemiological analysis starts by 
looking at a review of data from that period and beyond (Nelson et al., 2006).  
Adult trends were gathered from the National Health Interview Surveys from 
1987, 1991, 1992, 1994, 1998, and 2000.  Each year had anywhere between 
98,000 and 128,000 adult participants.  As defined by this survey, users were 
“those who had used either chewing tobacco or snuff 20 or 
more times in their life and who reported that they were 
now current users of either product” (Nelson et al., 2006). 
 
 Adult smokeless tobacco use had a steady decline between 1987 and 
2000 with an average annual percentage point change of -0.08.  Assessing men 
specifically shows a -0.14 percentage point change.  The only demographic 
subgroup that displayed increased smokeless tobacco use over this period and 
had a positive annual percentage point change (+ 0.02) included users between 
the ages of 25 and 44 years.  Overall, the decrease in adult use approached a 
total of 26% over the study period (Nelson et al., 2006). 
 Nelson et al. also analyzed the adolescent user trend during this period by 
using The National Institute for Drug Abuse’s Monitoring the Future (MTF) 
survey.  The MTF survey looked at 8th, 10th, and 12th grade students’ smokeless 
tobacco use.  A range of 130 to 150 schools were evaluated annually; both 
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private and public institutions were considered.  Questionnaires for 12th graders 
were available from the years 1986 to 1989, and 1992 to 2003.  Similar 
questionnaires were available for 8th and 10th graders from 1991 to 2003.  Also 
investigated was the CDC’s Youth Risk Behavior Survey (YRBS), given across 
the nation, from the years 1991 to 1993, 1995 to 1999, and 2001 to 2003.  In 
both the MTF and YRBS, smokeless tobacco use was defined as any adolescent 
who had used either chewing tobacco or snuff once or more in the past 30 days 
(Nelson et al., 2006). 
 By exploring the MTF surveys, the overall average annual percentage 
point changes of 8th, 10th, and 12th graders from the early 1990s was calculated 
at -0.36, -0.38, and -0.24, respectively.  Since adolescent girl smokeless tobacco 
use is very low and unchanged over this period, focusing at changes in 
adolescent boy use proved to be much more significant.  Boys in the 8th, 10th, 
and 12th grade had an average annual percentage point change of -0.62, -0.74, 
and -0.50, in that order.  The MTF surveys show a relative decrease of use of 
48% for 8th and 10th graders, and 43% for 12th grade boys.  In comparison, the 
YRBS displayed an average annual percentage point change of -0.38 among 
adolescents.  Again, when focusing on adolescent boys only, this value 
increased to -0.76; overall, this represents a decrease in adolescent use of 43% 
(Nelson et al. 2006). 
One study of smokeless tobacco use determined the trends from 2000 
until 2010 by also using the National Health Interview Surveys, however the 
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researchers used more current versions of the surveys (2000, 2005, and 2010).  
The survey includes questions asked regarding both chewing tobacco and snuff 
products, specifically on whether those surveyed had tried either product, and if 
so, how frequently they used either.  While the survey participants included 
adults of all ages, in this study specific focus was given to the young adult 
demographic with the age range from 18 to 44 years as this group is seen to be 
particularly vulnerable to smokeless tobacco exposure.  A total of 86,270 adults 
participated across all three surveys (Bhattacharyya, 2012). 
 Results indicate that the number of adults who had ever tried chewing 
tobacco had increased from 7.1% to 9.2% over the study period.  Similarly, those 
who tried snuff also rose from 4.4% to 8.4%.  While the percent of adults who 
were frequent users of chewing tobacco was relatively unchanged over this ten 
year period, the percent of frequent snuff users significantly increased from 1.4% 
to 2.0%.  This resembles around 2.52 million and 4.34 million adult chewing 
tobacco and snuff users in 2010, respectively (Bhattacharyya, 2012). 
 When focus is shifted to the 18 to 44 year young adult subgroup, the 
number of participants who had tried chewing tobacco escalated from 8.4% to 
9.9%, while with snuff products the rise was from 5.7 to 11.8%.  Not unlike the 
adult demographic, frequent chewing tobacco use among young adults showed 
no change; however, snuff use changed significantly from 1.8% to 2.8%.  
Therefore, in 2010, approximately 1.52 million young adults used chewing 
tobacco and 2.89 million used snuff (Bhattacharyya, 2012). 
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 This study also evaluated risk factors for smokeless tobacco use, finding 
that being male, non-Hispanic, Caucasian, and a non-graduate of high school 
increased the risk of using smokeless chewing tobacco products.  Conversely, 
being older and having a higher family income were associated with decreased 
risk of use.  The same risk factors apply to snuff (Bhattacharyya, 2012). 
 While the previously reviewed studies provide a broad perspective on 
smokeless tobacco use in the United States, trends vary significantly when 
comparing one state to another.  Using data from the 2009 Behavioral Risk 
Factor Surveillance System, the CDC evaluated the state-specific prevalence of 
smokeless tobacco use among adults.  According to the CDC, the Behavioral 
Risk Factor Surveillance System is a 
“state-based, landline telephone survey of non-
institutionalized adults conducted annually in all 50 states, 
the District of Columbia (DC), Guam, Puerto Rico, and 
USVI [the U.S. Virgin Islands].” 
 
The survey included 432, 607 adults with a 52% response rate when including 
those eligible who did not finish the survey or were not contacted (CDC, 2010). 
 The results of the CDC evaluation exhibited a wide range of smokeless 
tobacco use among the states and territories included, from 0.8% in the USVI to 
9.1% in Wyoming.  Alongside Wyoming, West Virginia (8.5%) and Mississippi 
(7.5%) had the highest observed use.  On the opposite end of the spectrum with 
the USVI were California (1.3%), DC (1.5%), and Massachusetts/Rhode Island 
(1.5% each).  Figure 4 provides a graphic of smokeless tobacco prevalence 
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among the states and clearly shows significant use in the southeastern, mid-
western, and northwestern regions (CDC, 2010). 
 
Figure 4: Prevalence of smokeless tobacco use among adults, by state (CDC, 
2010). 
 
In all states and territories, males used smokeless tobacco products more 
than females.  Smokeless tobacco use was most prevalent in those males 
between the ages of 18 and 24 years who had less than a high school education, 
a similar finding to the earlier study.  Across all included areas, the range of use 
among those with less than a high school education was 0.6% to 14.2%.  Those 
in the upper tier of education (college degree or further) displayed a prevalence 
of 0.9% to 6.1% (CDC, 2010). 
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Sweden 
 Use of snus in Sweden has increased dramatically since its surge in the 
late 1960s, overtaking cigarette sales around 1996, but it has been around since 
the beginning of the 1800s (Rutqvist et al., 2011).  The replacement of smoking 
with moist snuff (snus) has led to this change in snus use.  Overall use of 
tobacco (smoking and smokeless) was stable from 1986 to 1999 even with the 
use of cigarettes dropping 9%; this was countered by a simultaneous 8% 
increase in snus use (Rodu et al., 2002).  In fact, smokeless tobacco is so 
popular in Sweden that it has the highest consumption of snuff as a country, 
primarily of the snus variety (Luo et al., 2007).   
 The 2012 National Public Health report offered the most useful data on 
snus use in the Swedish population.  Figure 5 shows a breakdown of daily snus 
use, surveyed at the end of four different decades, for different age groups and 
gender.  The highest prevalence of snus use for men is seen in the 25-44 years 
age range, with use at 31% (Danielsson, Gilljam, & Hemstrom, 2012).  
Adolescent males (16-24 years) have the next highest percentage of snus use 
with 26.5%.  Unlike their male counterpart, adolescent females use snus the 
most for their gender at just under 5%.  For all men between the ages of 16 and 
84, 21% use snus daily. (Danielsson et al., 2012). 
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Figure 5: Daily snus use of males and females from different decades 
(Danielsson et al., 2012) 
 
India 
 Unfortunately, prevalence studies for smokeless tobacco and gutkha 
usage are difficult to establish.  For one, response rates and participation across 
India in smokeless tobacco surveys are significantly low.  Additionally, 
determining the incidence of Areca nut and gutkha use separately is difficult as 
different studies vary in their classification of both (Gupta et al., 2002).  
Nonetheless, regional epidemiological studies on smokeless tobacco and gutkha 
use do provide a perspective of prevalence. 
 Worldwide, it is estimated that approximately 10 to 20% of the population 
uses Areca nut of some kind.  A study of the inhabitants in Bombay, India, 
revealed a 32.1% prevalence rate for gutkha usage.  In that same population, the 
use of Areca nut or betel quid without tobacco was considerably lower at a 0.5% 
rate.  Among those included in the study, the prevalence of gutkha use was 
higher in men than women at a rate of 34.5% to 27.2% (Gupta et al., 2002). 
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 Using some earlier epidemiological surveys on gutkha use, comparisons 
can bet drawn between rural populations and those populations living in an urban 
environment.  A survey given to the inhabitants of the rural Bahavnagar District in 
Gujarat, India, detailed tobacco and areca-nut use.  A total of 3124 surveyed 
male villagers (27.7%) in this district had chewing habits of either areca-nut or 
tobacco, mixed or alone.  The majority of males (20.4%), however, used the 
ingredients simultaneously in various forms of gutkha.  The same could not be 
said about the surveyed female villagers; only 11.7% chewed areca-nut or 
tobacco and all except 0.1% were only dry snuff users (Gupta et al., 1998). 
 Surveyed inhabitants of Indian urban areas provided results that paralleled 
those of the rural regions with respect to male habits, but not with regards to 
females.  In Trivandrum, a city in the Kerala state, men and women of low 
socioeconomic status were asked about areca nut and tobacco chewing habits.  
The survey shows 26.8% of the 25,453 male participants and 26.4% of the 
34,441 female responders admitted to having gutkha habits (Sankaranarayanan 
et al., 2000).  Urban participants of lower socioeconomic status have more 
similarities with rural inhabitants than wealthier urban groups, so perhaps this is 
why male gutkha habits for both regions emulate one another.  There was no 
explanation discussed for the seemingly high gutkha habit prevalence in the 
female urban population. 
Currently, gutkha is being heavily marketed towards the Indian youth 
population; the effectiveness of these campaigns is observed in the study of a 
 35 
small Indian fishing village.  In this location, 27.4% of 5 to 20 year old boys use 
gutkha.  As seen in the epidemiologic studies in the United States, education 
level also seems to play a role in determining those at risk for smokeless tobacco 
usage in India, with less use associated with higher education levels.  A survey of 
1200 Indian college students in the Maharashtra state revealed 9.6% of the 
participants used gutkha, a significantly less than the rate found in the Bombay 
study (Hans, 1998). 
 
Smokeless Associated Cancer Risk 
 Now that smokeless tobacco trends and carcinogenicity have been 
established, the next logical step is to review studies determining the cancer risk 
associated with using the different regional products.  Proposed carcinogenic 
mechanisms may explain how cancers may be instigated, but do not necessarily 
explain how often.  Moreover, comparing dose dependent cancer risk profiles for 
each smokeless tobacco type with their respective user habits may reveal how 
safely the products are being used. 
 
United States 
 The largest cancer study examined was a meta-analysis of cancer risk 
estimates associated with smokeless tobacco.  The authors reviewed decades of 
epidemiological studies for past and present North American and Swedish 
products.  A total of 89 studies were included in the meta-analysis, with a wide 
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variety of cancer types covered, and only those studies performed within the 
regions analyzed (North America and Europe) were included (Lee and Hamling, 
2009).  When appropriate, relative risk (RR) estimates were presented for never-
smokers if studies provided such information.  For each cancer variety, RR 
estimates were combined from the associated studies and an overall RR 
estimate was calculated.  Any value noted as “adjusted for smoking” means that 
the influence of smoked tobacco to the RR calculated was removed from the 
calculation.  Methods for performing this adjustment vary so smoked tobacco 
influence may be over or under estimated. 
 Disregarding the Swedish studies involving snus for future review, the 
results of the meta-analysis can be seen on Table 3.  Smokeless tobacco use 
shows a significant RR elevation for oropharyngeal cancer in the US, along with 
several other cancer groupings.  The very high RR value of 3.33 for 
oropharyngeal cancer among participants who have never smoked was 
determined much higher than the overall RR calculated for this variety of cancer, 
but only 5 studies contributed to the never-smoked RR (Lee and Hamling, 2009).  
Once adjusted for smoking, the relative risks for oropharyngeal, esophageal, and 
larynx cancer associated with smokeless tobacco were 1.65, 1.89, and 2.01, 
respectively.  Interestingly, when only including studies that focus on 
oropharyngeal cancer after the year 1990 (a total of 18 studies), the RR estimate 
drops from 1.65 to 1.28 (Lee and Hamling, 2009).  A decrease of this magnitude 
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reflects the lower carcinogenic levels associated with modern era smokeless 
tobacco when compared to earlier products. 
 
Table 3: Meta-analysis results of smokeless tobacco associated cancer risk in 
the United States. ‘n’ displays the number of study estimates used, ‘RR’ refers to 
relative risk, and ‘CI’ is the confidence interval (Lee and Hamling, 2009). 
 
Cancer Type Overall Data 
(n) RR (95% CI) 
Smoking Adjusted 
(n) RR (95% CI) 
Never Smokers 
(n) RR (95% CI) 
Oropharyngeal (31) 2.16 (12) 1.65 (5) 3.33 
Esophageal (6) 1.56 (3) 1.89 (3) 1.89 
Laryngeal (4) 1.56 (1) 2.01 - 
 
While the large scope of this meta-analysis provides stronger RR estimates than 
an individual study, some conclusions are left to be desired.  For example, 
relative few of the studies included in the meta-analysis reported on dose or 
frequency of smokeless tobacco use; frequency of exposure plays a critical role 
in carcinogenesis and would explain differing RRs.  Additionally, each study 
varies in participant pool, exclusion and inclusion criteria, methods of 
assessment, and other parameters.  Moreover, even though only chewing 
tobacco and snuff products were examined, many different brands were 
encountered.  Lastly, some studies did not specify whether or not the RR 
estimates were determined from current or former users of smokeless tobacco 
(using old or current products).  All weaknesses aside, Lee and Hamling 
concluded that “the consistency of these findings suggest that smokeless 
 38 
tobacco may increase the risk of cancer” although this risk is “clearly very much 
less than that from smoking.” 
 Another meta-analysis considered, authored by Weitkunant, Sanders, and 
Lee combined the results of 32 separate studies.  In comparison, the selection of 
studies was much more specified than those seen in Lee and Hamling’s meta-
analysis with extensive inclusion and exclusion criteria.  Also, the analysis only 
included cancer risk assessments for the most common of oral cancers, 
squamous-cell carcinoma. 
 The fifteen studies included in the meta-analysis focusing on the US 
region displayed a mean RR of 1.76 for oral cancer from smokeless tobacco use.  
Ten of these studies adjusted for smoking, and with those intrusive variables 
calculated out, the resulting mean RR was 1.39 (Weitkunat, Sanders, and Lee, 
2007).  As seen in the adjusted smoking RR calculated in the Lee meta-analysis, 
oral cancer (oropharyngeal cancer) RR decreased with the influence of smoking 
removed.  The analysis concludes that 
“at most a minor increased risk of oral cancer [is] 
associated with the use of a wide range of currently used 
Western chewing tobacco and snuff” (Weitkunat, Sanders, 
and Lee, 2007). 
 
 
Though the meta-analysis provides a good estimate for oral cancer risk, 
changes could strengthen the results.  For one, studies from as early as the 
1920s met the inclusion criteria and were included even though they do not 
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reflect modern day risk.  Also, the number of RR estimates adjusted for smoking 
was limited. 
 
Sweden 
 Epidemiological data reviewed displayed a relatively high percentage of 
snus use in the Swedish population compared to smokeless tobacco use in the 
United States.  Fortunately, for research purposes, the popularity of snus is 
matched by an increase in research on its effects on health, specifically 
regarding oral malignancies.  Several of these studies were reviewed to 
determine the magnitude of risk involved with snus use. 
 The objective of a study by Roosar et al. was to calculate the cancer 
incidence in male users of snus.  In this cohort study, 9,976 total participants 
were selected in 1973; the males were all from Uppsala, Sweden, and needed to 
be above the age of 15.  Individuals with previous cancers were excluded, as 
were women, since little snus use was observed in their population (Roosar et 
al., 2008).  Upon follow-up in 2002, participants either were placed in “never daily 
use” or “ever daily use” groups for snus use.  Participant incidences of cancer 
and death (from cancer or other factors) were recorded.  Factors such as alcohol 
and smoking tobacco were adjusted for. 
 Collected results showed that 9% of participants were ever daily users of 
snus, 53% were ever daily smokers, and 7% were ever daily users of both.  
There was no significant increase of any cancer incidence in ever daily users of 
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snus (RR of 0.99) when compared to never daily users, even when adjusted for 
smoking and alcohol (Roosar et al., 2008).  When focusing only on smoking-
related cancers, such as those in the oral cavity, lungs, and larynx, there was 
only a minor 1.1 RR for snus users (not adjusted for smoking).  Only with focus 
particularly on oropharyngeal cancers was a real increase of risk noted; this had 
a RR value of 3.1 among users of snus (Roosar et al., 2008).  For the overall 
mortality of snus users, the RR for death was merely 1.10, a slim elevation 
(adjusted for smoking).  These RR measures argue against the popular claim 
that snus is a healthy alternative to smoking and that the results are “inconsistent 
with claims that the use of [Swedish] moist snus is without demonstrable risk” 
(Roosar et al., 2008).  However, older participants may have been exposed to 
more of the earlier, high-concentration TSNA products than younger participants, 
possibly altering the calculated RR from the modern day RR. 
 A second cohort review studied Swedish construction workers, men who 
had a high prevalence of snus exposure, and established a RR for oral cancer.  
The study began in 1978 and continued until the final follow-up in 1992.  For the 
279,897 participants, information on snus use, grams used daily, smoking status, 
and grams of smoking used daily was gathered (Luo et al., 2007).  RR 
associated for snus use was adjusted for smoking when necessary. 
 A total of 31% of the participants had or were currently using snus, a 
slightly higher percentage than that established for all Swedish men.  Of the 
125,576 participants who had no history of smoking tobacco use, there were 60 
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oral cancer incidences (Luo et al., 2007).  Surprisingly, the RR estimated for oral 
cancer from snus use was 0.8, less than participants who had never used any 
tobacco product.  Ten of the 60 oral cancer incidences were from snus users, the 
other 50 incidences represented users who had never used tobacco.  An 
increase of RR, albeit a slight increase, would be expected.  Of the 154,321 ever 
smokers, the RR associated with smoking and oral cancer was 2.0 (198 cases) 
(Luo et al., 2007).  The lack of an increase of oral cancer RR for snus users 
conflicts with the previous studies results.  Perhaps the lack of variation in the 
participant pool is partly responsible for this unusual end result. 
 
India 
 The first study reviewed oropharyngeal cancer cases from three separate 
hospital centers in Nagpur, a central Indian city.  A total of 123 cases of 
oropharyngeal cancer were included when determining RR estimates associated 
with tobacco.  For the study participants, tobacco habits were recorded which 
revealed dose, frequency of use, composition of tobacco mix used, and other 
related metrics.  Most of the participants were male (59%) and between the ages 
of 41 and 60 (67%) (Wasnik et al., 1998).  A large percentage (42.3%) of the 
cancer patients used gutkha, and over 61% of the participants used tobacco 
products 6 or more times a day.  The largest percentage of patients had been 
using tobacco chewing products for 20 and 40 years (Wasnik et al., 1998). 
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 Overall, analysis of the data generated a 7.98 RR for oropharyngeal 
cancer associated with chewing tobacco use.  For comparison, a 2.25 RR was 
found for smoking tobacco use (Wasnik et al., 1998).  Probing into the individual 
RRs for chewing tobacco use, the RR generated with only gutkha use was 8.25; 
for betel nut alone, an 1.85 RR was established.  As expected, an increase in 
either the daily frequency of use or lifetime duration of use was matched with an 
increase in RR for oropharyngeal cancer.  These RR estimates as a whole 
provide evidence that gutkha use significantly increases your risk for oral cancer 
(Wasnik et al., 1998). 
 A weakness in this study, and with most gutkha studies, is the wide 
variation in gutkha composition used by participants.  The lack of standardization 
makes it difficult to make claims regarding the risks of gutkha as a whole if a 
standard product is nonexistent. 
 The other study used information gathered from the Bhopal Cancer 
Registry database out of Bhopal, India.  A total of 247 oropharyngeal cancer 
cases and 148 oral cavity cancer cases were evaluated based on tobacco habits 
and history.  In regards to oropharyngeal cancer, the RR associated with gutkha 
use was 1.1, and 1.2 when adjusted for smoking (Dikshit and Kanhere, 2000).  A 
much more significant increase in RR was found when reviewing the oral cavity 
cancer cases.  The RR for this cancer type when associated with gutkha was 5.5, 
and 5.8 when adjusted for smoking (Dikshit and Kanhere, 2000).  Daily-dosage 
and lifetime exposure to gutkha both greatly influenced the RR of both cancers 
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involved.  For instance, if gutkha was only chewed between 1 to 5 times daily, a 
0.5 RR for oropharyngeal cancer and a 2.0 RR for oral cancer was estimated.  
However, at the extreme level with gutkha chewed over 10 times a day, these 
values saw an increase to 3.6 and 13.9, respectively (Dikshit and Kanhere, 
2000).  Similar trends were seen with length of gutkha habit (in years), with much 
higher RRs estimated for longer gutkha habits. 
 
Discussion and Conclusion  
 Clearly, the use of smokeless tobacco is embedded in the cultures of 
many differing global regions.  While the presence of smokeless tobacco is 
common, the variety of the smokeless tobacco product and associated public 
health impact vary considerably.  Together, the differing products, health 
consequences, and usage trends seen in India, Sweden, and North America 
demonstrate the relative safety of each region’s smokeless tobacco environment. 
 When comparing the carcinogenic profiles of each region’s associated 
smokeless tobacco product, there seems to be a direct association between 
production standards and carcinogen exposure.  The carcinogenic levels shown 
for TSNA concentration in gutkha products vary wildly and reached 
extraordinarily high levels, reflecting its disordered manufacturing.  While 
commercial gutkha products are available in many Indian districts, much gutkha 
is of the homemade variety through the combination of betel quid and chewing 
tobacco.  Therefore, the amount of tobacco used (and consequently the amount 
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of TSNA) is dependent on individual desires.  Smokeless tobacco products in the 
United States, on the other hand, show more consistency in the TSNA levels.  
While particular smokeless tobacco types vary in carcinogen levels (for instance, 
a mean of 9786 ng/g total TSNA in moist snuff compared to 3350 ng/g in loose 
leaf), the individual brands of each type are reasonably similar in constituent 
concentrations (Borgerding et al., 2012).  However, Sweden displayed the most 
stable mean total TSNA values in their snus as well as the lowest, both a result 
of the strict manufacturing policies in place. 
 While snus has been around for decades, only since 1971 has snus 
manufacturing been regulated under the Swedish Food Act (Rutqvist et al., 
2011).  Known since its conception that year as the GothiaTek® standard, 
Swedish snus production follows stringent protocol and quality control.  Included 
in the protocol, heating the snus was initially performed to eliminate an earlier 
microbial problem; lower TSNA values are responsible for the continued use of 
the heating process.  To this day, the GothiaTek® standard (current standard set 
in 1990) also determines maximum acceptable TSNA levels, criteria for natural 
material selection, and the required information to be displayed to consumers 
(Rutqvist et al., 2011).  Consequently, the Tobacco Regulatory Committee of the 
World Health Organization has determined that Swedish snus has one of the 
lowest TSNA concentrations on the global smokeless tobacco market (World 
Health Organization Study Group on Tobacco Production Regulation, 2009). 
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While gutkha and American smokeless tobacco products both fall under 
the authority of their respective government’s Food and Drug Administration, this 
authority is comparatively young when compared to Sweden’s (Swedish Food 
Act) by several decades.  If both the United States and India adopt stricter 
manufacturing guidelines for domestic smokeless tobacco manufacturers to 
reflect the GothiaTek® standard, more products may exhibit the TSNA levels 
seen in snus.  Perhaps this change would lower the RR for oral cancers 
associated with gutkha and American products similar to Swedish snus. 
 With reference to the RR for oral cancers, the reviewed cancer studies 
clearly demonstrated that the highest association between smokeless tobacco 
use and the development of oral cancer was observed with gutkha products.  
The RR associated with gutkha use was greater than that of US smokeless 
tobacco products by a factor between 3 and 4, and even more so when 
compared to the RR associated with Swedish snus.  The difficulty encountered 
when interpreting the results for the RR associated with gutkha use is 
determining which constituents are most carcinogenically significant, the TSNAs 
or the betel quid.  This difficulty is compounded when factoring in how unique the 
constituent blends can be among gutkha products.  While the RR for oral cancer 
associated with pure betel quid use was mentioned in one of the studies (1.85), it 
is unknown whether or not areca nut and tobacco carcinogens interact with one 
another, possibly increasing (or decreasing) carcinogenicity (Wasnik et al., 
1998). 
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The extremely low (and possibly nonexistent) increase in the RR for oral 
cancers associated with Swedish snus was particularly interesting.  TSNA 
presence in snus would typically point toward an increase in carcinogenicity, and 
thus a rise in RR.  In order to further explore the specific carcinogenicity of 
Swedish snus, a toxicology study was reviewed. 
The early section discussing the TSNA’s carcinogenic mechanisms may 
have explained how the TSNA found in tobacco products cause damage that 
may lead to eventual tumorigenesis, but an investigative approach to the 
toxicology of Swedish snus provides conflicting results in the laboratory of 
Coggins and colleagues.  The purpose of the study was to determine if Swedish 
snus was active in four popular in vitro toxicology assays that are used to predict 
and determine the carcinogenicity of a substance.  The products tested included 
three popular Swedish snus brands and a moist snuff reference.  The four 
assays used were: The Ames assay (S. typhimurium reverse-mutation assay), 
the mouse lymphoma assay (MLA), an in vitro micronucleus assay (MNAvit), and 
the neutral red uptake (NRU) assay.  Each sample was formed and extracted 
(500 mg of product per mL of extract) and further diluted to be tested.  The 
consistency of concentrations was determined by testing the nicotine content of 
each extract (Coggins et al., 2012). 
 The Ames assay tests for the mutagenic and carcinogenic potential of a 
sample by determining whether or not the sample can revert a mutated S. 
typhimurium strain back to its natural state.  If a compound exhibits carcinogenic 
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characteristics, the strain will show signs of reverting (Mortelmans and Zeigar, 
2000).  Numerous concentrations of each extract were tested on petri dishes, 
with results measured in revertant (“reverted”) colonies.  The presence of 
revertant colonies shows mutagenic potential; more colonies present are 
associated with a substance having a higher mutagenic potential.  Of all the 
extract concentrations analyzed, only the two highest concentrations provided 
results of significant levels, concentrations which were “well above those 
suggested by regulatory guidelines” for snus use and not found commercially 
(Coggins et al., 2012).  The three other assays (the MLA, MNAvit, and NRU) 
displayed similar results concerning the toxicity of snus. 
With the exception of snus extract concentration levels far exceeding 
commercial levels, no significant positive results were demonstrated, suggesting 
that snus is not significantly carcinogenic.  On the other hand, the moist snuff 
reference demonstrated significant positive results in both the Ames assay and 
MLA, and a positive control confirmed the accuracy of the assays used.  
Although interpretation of positive assay results vary among those in the field,  
the Coggins’ study claims Swedish snus to be less carcinogenic than traditional 
moist snuff and significantly less carcinogenic than cigarettes (Coggins et al., 
2012). 
Even so, the carcinogenic potential of these regions’ products only affect 
those who use them.  Keeping up with the previous trend, gutkha use is highest 
with its respective region’s population, followed by snus in Sweden and then 
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lastly the smokeless tobacco products in the United States.  The research 
reviewed earlier revealed gutkha use by males in India ranged from around 20% 
to just over 30%, and slightly lower for females (Gupta et al., 2002).  Male snus 
use in Sweden is comparable to the lower range of male gutkha use in India, but 
the female population in Sweden uses smokeless tobacco products far less than 
in India.  Smokeless tobacco use in the United States is significantly lower than 
either the Indian or Swedish population, not even surpassing a 10% user base in 
any state (CDC, 2010). 
The varying cultures and perspectives on smokeless tobacco account for 
the differences in the percentage of smokeless tobacco users.  As stated earlier, 
gutkha use is deeply engrained in many Indian societies’ traditions which may 
explain the large user base.  However, as information on the detrimental effects 
of gutkha spreads, the Indian government has begun banning its sale.  For 
instance, the Indian state of Maharashtra had areca nut products banned from 
the market in 2002, including gutkha (Sharan et al., 2012).  Unfortunately, the 
public circumvents these restrictions by purchasing the constituents separately, 
sometimes from surrounding states, and making their own gutkha products. 
In the United States, cigarettes remain to this day the preferred method of 
tobacco consumption.  The slight rise in smokeless tobacco use seen in the 
United States (and simultaneous slight decrease in smoking tobacco use) is 
partially a result of the tobacco industry encouraging the use of smokeless 
tobacco where cigarettes and cigars have been recently banned (Bhattacharyya, 
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2012).  The shift from smoking to smokeless tobacco may continue if restrictions 
on smoking tobacco tighten further and the tobacco industry increases the 
marketing of snuff (Richter et al., 2008). 
In Sweden, the belief of snus as a “healthier” alternative to other tobacco 
options, especially cigarettes, holds much of the responsibility for the increase in 
snus users over the decades (Roosar et al., 2008).  With the low TSNA 
concentrations found in snus products and comparative RR for oral cancers 
between snus and smoking tobacco, snus seems to be less harmful.  To 
distinguish snus as a “healthy” alternative seems misleading, though.  TSNAs are 
carcinogens no matter their concentration, and no matter how slight the increase 
in RR for cancer is found to be, the risk is higher than if tobacco was not 
consumed at all. 
Although none of the smokeless tobacco products studied can be 
considered safe, each region differs in the severity and potential danger of their 
smokeless tobacco habits.  With the highest associated RR for oral cancer, most 
carcinogens, and highest percentage of users, gutkha has a significant 
detrimental effect on the public health of India.  Luckily, recent actions are being 
taken to address this issue.  Swedish snus may appear much safer than gutkha, 
particularly at the chemical level, but the large male user population is still 
exposing itself to unnecessary toxins that are linked to oral cancer.  The 
tendency to refer to snus as a healthy tobacco option has to change.  Finally in 
the United States, where the imprint of smokeless tobacco products may 
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currently be small, recent trends provide a glimpse at a future problem if snuff 
use continues to increase.  Measures must be taken to discourage the use of any 
tobacco products, including snuff, to avoid usage trends presently seen in 
Sweden and India. 
 
Future Research 
Most of the cancer risk studies reviewed were long-term cohort studies, 
spanning several decades of smokeless tobacco use.  As TSNA levels in 
smokeless tobacco products have decreased drastically over this same time 
period, some of the cancer cases recorded will be a consequence of the earlier, 
more carcinogenic products.  Future studies should try to include only those 
users who have used the more modern products which will reflect the current 
market better. 
Additionally, it would be interesting to test the toxicology of Indian gutkha 
products with different constituents removed.  By running Ames (and similar) 
tests on a gutkha product, once with the areca nut ingredients removed and once 
with the tobacco ingredients removed, it may be possible to compare the 
carcinogenicity of individual constituents in a single product. 
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